Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis.

Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, Gluch A, Kel A, Sangfelt O, Selivanova G.

Cancer Cell. 2017 May 8;31(5):724-726. doi: 10.1016/j.ccell.2017.04.014. No abstract available.

2.

Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis.

Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, Gluch A, Kel A, Sangfelt O, Selivanova G.

Cancer Cell. 2009 May 5;15(5):441-53. doi: 10.1016/j.ccr.2009.03.021. Erratum in: Cancer Cell. 2017 May 8;31(5):724-726.

3.

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.

Burmakin M, Shi Y, Hedström E, Kogner P, Selivanova G.

Clin Cancer Res. 2013 Sep 15;19(18):5092-103. doi: 10.1158/1078-0432.CCR-12-2211. Epub 2013 Jul 17.

4.

RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.

Saha MN, Jiang H, Mukai A, Chang H.

Mol Cancer Ther. 2010 Nov;9(11):3041-51. doi: 10.1158/1535-7163.MCT-10-0471. Epub 2010 Nov 9.

5.

RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis.

Kazemi A, Safa M, Shahbazi A.

Hematology. 2011 Jul;16(4):225-31. doi: 10.1179/102453311X12953015767536. Erratum in: Hematology. 2011 Sep;16(5):324.

PMID:
21756539
6.

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.

Surget S, Descamps G, Brosseau C, Normant V, Maïga S, Gomez-Bougie P, Gouy-Colin N, Godon C, Béné MC, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.

BMC Cancer. 2014 Jun 14;14:437. doi: 10.1186/1471-2407-14-437.

7.

Chk2 mediates RITA-induced apoptosis.

de Lange J, Verlaan-de Vries M, Teunisse AF, Jochemsen AG.

Cell Death Differ. 2012 Jun;19(6):980-9. doi: 10.1038/cdd.2011.182. Epub 2011 Dec 9.

8.

p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA.

Hedström E, Eriksson S, Zawacka-Pankau J, Arnér ES, Selivanova G.

Cell Cycle. 2009 Nov 1;8(21):3584-91. Epub 2009 Nov 1.

PMID:
19838062
9.

Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.

Ma T, Yamada S, Ichwan SJ, Iseki S, Ohtani K, Otsu M, Ikeda MA.

Biochem Biophys Res Commun. 2012 Jan 20;417(3):931-7. doi: 10.1016/j.bbrc.2011.11.161. Epub 2011 Dec 6.

PMID:
22166212
10.

RITA enhances irradiation-induced apoptosis in p53-defective cervical cancer cells via upregulation of IRE1α/XBP1 signaling.

Zhu H, Abulimiti M, Liu H, Su XJ, Liu CH, Pei HP.

Oncol Rep. 2015 Sep;34(3):1279-88. doi: 10.3892/or.2015.4083. Epub 2015 Jun 25.

PMID:
26134873
11.

The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.

Roh JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM.

Cancer Lett. 2012 Dec 1;325(1):35-41. doi: 10.1016/j.canlet.2012.05.020. Epub 2012 May 22.

PMID:
22634494
12.

RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.

Weilbacher A, Gutekunst M, Oren M, Aulitzky WE, van der Kuip H.

Cell Death Dis. 2014 Jul 10;5:e1318. doi: 10.1038/cddis.2014.284.

13.

Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.

Saha MN, Jiang H, Yang Y, Zhu X, Wang X, Schimmer AD, Qiu L, Chang H.

PLoS One. 2012;7(1):e30215. doi: 10.1371/journal.pone.0030215. Epub 2012 Jan 20.

14.

Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.

Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G.

Cell Cycle. 2010 May;9(9):1847-55. Epub 2010 May 15.

PMID:
20436301
15.

IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.

Di Conza G, Buttarelli M, Monti O, Pellegrino M, Mancini F, Pontecorvi A, Scotlandi K, Moretti F.

Mol Cancer Ther. 2012 Jun;11(6):1247-56. doi: 10.1158/1535-7163.MCT-11-0913. Epub 2012 Mar 28.

16.

Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.

Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F.

Cell Cycle. 2014;13(4):652-65. doi: 10.4161/cc.27546. Epub 2013 Dec 17.

PMID:
24345738
17.

Efficient synthesis of RITA and its analogues: derivation of analogues with improved antiproliferative activity via modulation of p53/miR-34a pathway.

Lin J, Jin X, Bu Y, Cao D, Zhang N, Li S, Sun Q, Tan C, Gao C, Jiang Y.

Org Biomol Chem. 2012 Dec 28;10(48):9734-46. doi: 10.1039/c2ob26627j. Epub 2012 Nov 15.

PMID:
23151607
18.

Mutated and non-mutated TP53 as targets in the treatment of leukaemia.

Nahi H, Selivanova G, Lehmann S, Möllgård L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C.

Br J Haematol. 2008 May;141(4):445-53. doi: 10.1111/j.1365-2141.2008.07046.x. Epub 2008 Mar 12.

PMID:
18341636
19.

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.

Michaelis M, Rothweiler F, Agha B, Barth S, Voges Y, Löschmann N, von Deimling A, Breitling R, Doerr HW, Rödel F, Speidel D, Cinatl J Jr.

Cell Death Dis. 2012 Apr 5;3:e294. doi: 10.1038/cddis.2012.35.

20.

Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation.

Zhao CY, Szekely L, Bao W, Selivanova G.

Cancer Res. 2010 Apr 15;70(8):3372-81. doi: 10.1158/0008-5472.CAN-09-2787. Erratum in: Cancer Res. 2017 Jul 1;77(13):3719.

Supplemental Content

Support Center